Mylan NV received board approval to repurchase up to $1 billion of its shares, three days after losing its hostile bid for Perrigo Co.

The authorization expires Aug. 27, 2016.

Mylan Executive Chairman Robert Coury said the board's authorization "provides us with optimal flexibility and allows us to be opportunistic in repurchasing shares, thereby investing in Mylan's strong growth prospects and exciting future, which we continue to believe are substantially undervalued."

Mylan suffered defeat Friday in a landmark hostile takeover bid, dealing a blow to the generic-drug maker.

Perrigo shareholders rejected Mylan's $26 billion takeover offer, the companies said Friday. The outcome surprised many analysts and investors who predicted Mylan would eke out a victory in its pursuit of Dublin-based Perrigo, which principally makes store-brand versions of cold and allergy medicines.

Write to Anne Steele at Anne.Steele@wsj.com

 

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

November 16, 2015 12:35 ET (17:35 GMT)

Copyright (c) 2015 Dow Jones & Company, Inc.
Mylan NV (NASDAQ:MYL)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Mylan NV Charts.
Mylan NV (NASDAQ:MYL)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Mylan NV Charts.